Skip to main content

Table 1 Clinicopathological data of MMR-defective tumors

From: Low frequency of defective mismatch repair in a population-based series of upper urothelial carcinoma

Case no. Sex / Age Tumor location (Synchron./Metachron.) WHO-Grade Stage Instable markers Immunohistochemical expression
       MLH1 MSH2 MSH6 PMS2
U1-113 F/54 ureter G2 pTX NE + - - +
  53 endometrium (M)    4/6 + - - +
U2-229 F/57 ureter G2 pT1 4–5/6 - + + -
  57 ureter (S)    4–5/6 - + + -
U3-821 M/61 ureter* G2 pT1 2–3/6 + - - +
RP1-101 M/60 renal pelvis G2 pT3 3/5 + - - +
  43 sarcoma (M)    3/4 + - - +
  53 colon (M)    1/6¤ + - - +
RP2-131 M/75 renal pelvis G3 pT4 2/6 + + + +
RP3-119 F/69 renal pelvis G3 pTa 0/6 - + NE -
RP4-267 F/67 renal pelvis G2 pT1 5/5 + - - +
  70 urinary bladder (M)    3/4 + - - +
RP5-401 M/56 renal pelvis G2 pTa 0/6 + + - +
RP6-528 F/87 renal pelvis G2 pT1 2/5 + + + +
  87 urinary bladder (S)    0/6 + + + +
RP7-613 F/57 renal pelvis^ G2 pT1 3/6 + + - +
  54 urinary bladder (M)    4/6 + - - +
RP8-626 M/66 renal pelvis G3 pT2 6/6 + - - +
RP9-701 F/49 renal pelvis# G2 pTa 0/5 + - NE +
RP10-809 F/82 renal pelvis G3 pT4 4/4 + - - +
  1. ¤Positive for BAT26
  2. * Myelofibrosis at the age of 67 years.
  3. ^Cervical cancer at the age of 33.
  4. # Rectal tumor at the age of 38.
  5. G2 moderately differentiated
  6. G3 poorly differentiated